8800 related articles for article (PubMed ID: 16817687)
1. Comparative analysis of paracrine immunotherapy in experimental brain tumors.
Lesniak MS; Sampath P; DiMeco F; Viglione MP; Tyler BM; Pardoll DM; Brem H
Neurosurg Focus; 2000 Dec; 9(6):e4. PubMed ID: 16817687
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2.
Lesniak MS; Tyler BM; Pardoll DM; Brem H
J Neurooncol; 2003; 64(1-2):155-60. PubMed ID: 12952296
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors.
Lesniak MS; Gabikian P; Tyler BM; Pardoll DM; Brem H
J Neurooncol; 2004 Oct; 70(1):23-8. PubMed ID: 15527103
[TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines.
Tseng SH; Hwang LH; Lin SM
J Immunother; 1997 Sep; 20(5):334-42. PubMed ID: 9336740
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
Yu JS; Burwick JA; Dranoff G; Breakefield XO
Hum Gene Ther; 1997 Jun; 8(9):1065-72. PubMed ID: 9189764
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat.
Jean WC; Spellman SR; Wallenfriedman MA; Flores CT; Kurtz BP; Hall WA; Low WC
J Neurooncol; 2004 Jan; 66(1-2):39-49. PubMed ID: 15015768
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
10. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors.
Thompson RC; Pardoll DM; Jaffee EM; Ewend MG; Thomas MC; Tyler BM; Brem H
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):405-13. PubMed ID: 9041459
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
[TBL] [Abstract][Full Text] [Related]
12. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
14. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.
Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF
Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885
[TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
16. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
17. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
[TBL] [Abstract][Full Text] [Related]
18. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
[TBL] [Abstract][Full Text] [Related]
19. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
20. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
Mahvi DM; Burkholder JK; Turner J; Culp J; Malter JS; Sondel PM; Yang NS
Hum Gene Ther; 1996 Aug; 7(13):1535-43. PubMed ID: 8864754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
